CVS Health Corp (CVS) Stock Analysis
Verdict: WATCH (do not buy)
CVS is a high-volume, low-margin titan whose ~12% valuation gap is currently capped by heavy insider selling and elevated debt leverage.
Investment score: 58/100
Analysis as of
Is CVS Health Corp stock worth reviewing? AI model thesis
CVS exhibits a classic value trap profile balanced by strong FCF generation ($7.8B in 2025). High leverage and insider selling prevent a Buy rating.
7-factor investment score
- Valuation: 72/100 (weight 20%)
- Financial Health: 35/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 15/100 (weight 10%)
- Analyst Consensus: 78/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
CVS Health Corp opportunities and risks
What speaks for CVS
- AI-Driven Margin Recovery
What speaks against CVS
- Excessive Financial Leverage
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CVS | 39.4x | 0.3x | 16.6x | 13.9% | 0.7% | 6.4% |
| CI | 11.7x | 0.3x | 8.2x | 9.3% | 2.3% | 10.3% |
| DGX | 20.7x | 1.9x | 14.1x | 33.2% | 9.1% | 6.2% |
| LH | 22.6x | 1.5x | 13.2x | 27.8% | 6.7% | 6.5% |
| LH | 22.6x | 1.5x | 13.2x | 27.8% | 6.7% | 6.5% |
| GH | n/a | 14.7x | n/a | 64.9% | -40.1% | -1.4% |
| Peer median | 20.7x | 1.5x | 13.2x | 27.8% | 6.7% | 6.5% |
Frequently asked questions about CVS Health Corp (CVS)
Is CVS stock a good investment?
The cached TradeMates AI model rates CVS Health Corp as WATCH (do not buy) with an investment score of 58/100. CVS exhibits a classic value trap profile balanced by strong FCF generation ($7.8B in 2025). High leverage and insider selling prevent a Buy rating. This is algorithmic model output, not personal investment advice.
Is CVS stock a buy?
The TradeMates model verdict for CVS is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.